Retraction: Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: Involvement in chemosensitization to drug-induced apoptosis (Oncogene (2007) 26 (6184-6193) DOI: 10.1038/sj.onc.1210448);Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: Involvement in chemosensitization to drug-induced apoptosis

Oncogene

Volumn 26, Issue 42, 2007, Pages 6184-6193

  Suzuki, E ^a,b   Umezawa, K ^b   Bonavida, B ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akt pathway; Apoptosis; Chemosensitization; Rituximab

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B; RITUXIMAB; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER RESISTANCE; CELL LINE; CHEMOSENSITIZATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 34249734458     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.207     Document Type: Erratum

References (33)

1. Alas S, Bonavida B. (2001). Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61:5137-5144.
2. Arranz E, Robledo M, Martfnez B, Gallego J, Remain A, Rivas C et al. (1996). Incidence of homogeneously staining regions in non-Hodgkin lymphomas. Cancer Genet Cytogenet 87:1-3.
3. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
4. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK et al. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Sci USA 93:3636-3641.
5. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. (2005). The Akt/PKB pathway:molecular target for cancer drug discovery. Oncogene 24:7482-7492.
6. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM et al. (2004). A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18:139 1-1400.
7. Datta SR, Brunet A, Greenberg ME. (1999). Cellular survival: a play in three Akts. Genes Dev 13:2905-2927.
8. Di Cristofano A, Pandolfi PP. (2000). The multiple roles of PTEN in tumor suppression. Cell 100:387-390.
9. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. (2005). Isolation and Characterization of the B-Cell Marker CD20. Biochemistry 44:15150-15158.
10. Goswami A, Ranganathan P, Rangnekar VM. (2006). The phosphoinositide 3-kinase/Akt1/Par-4 axis:a cancer-selective therapeutic target. Cancer Res 66:2889-2892.
11. Haiman CA, Stram DO, Cheng I, Giorgi EE, Pooler L, Penney K et al. (2006). Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol Biomarkers Prev 15:1 021-1025.
12. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y et al. (2000). Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60: 5988-5994.
13. Jazirehi AR, Bonavida B. (2005). Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma:im plications in chemosensitization and therapeutic intervention. Oncogene 24:21 21-2143.
14. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. (2005). Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-\{kappa\}B signaling pathway in non-Hodgkin's lymphoma B-cell lines:role in sensitization to chemo. Cancer Res 65:264-276.
15. Jazirehi AR, Vega MI, Bonavida B. (2007). Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67:1270-1281.
16. Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. (2004). Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 64:71 17-7126.
17. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK et al. (2005). PTEN expression in non-small-cell lung cancer:evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36: 768-776.
18. Osaki M, Oshimura M, Ito H. (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676.
19. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
20. Poh TW, Pervaiz S. (2005). LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res 65:6264-6274.
21. Rennie PS, Nelson CC. (1998). Epigenetic Mechanisms for Progression of Prostate Cancer. Cancer Metastasis Rev 17: 401-409 Review.
22. Rogers BB. (2006). Overview of non-Hodgkin's lymphoma. Semin Oncol Nurs 22:67-72.
23. Shan D, Ledbetter JA, Press OW. (1998). Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644-1652.
24. Sugimori K, Matsui K, Motomura H, Tokoro T, Wang J, Higa S et al. (2005). BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/Akt-mediated NF-kappaB activation. J Bone Miner Metab 23:411-419.
25. Tachiiri S, Sasai K, Oya N, Hiraoka M. (2000). Enhanced cell killing by overexpression of dominant-negative phosphatidylinositol 3-kinase subunit, Deltap85, following genotoxic stresses. Jpn J Cancer Res 91:1314-1318.
26. Toker A, Yoeli-Lerner M. (2006). Akt signaling and cancer: surviving but not moving on. Cancer Res 66:3963-3966.
27. Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatiaa KG. (2004). Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 320:93 2-938.
28. Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
29. Weintraub SJ, Manson SR, Deverman BE. (2004). Resistance to antineoplastic therapy. The oncogenic tyrosine kinase-Bcl-x(L) axis. Cancer Cell 5:3-4.
30. Wetzker R, Rommel C. (2004). Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des 10: 1915-1922.
31. Xerri L, Parc P, Brousset P, Schlaifer D, Hassoun J, Reed JC et al. (1996). Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol 92: 900-906.
32. Yin D, Woodruff M, Zhang Y, Whaley S, Miao J, Ferslew K et al. (2006). Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3K/Akt/NF-kappaB pathways. J Neuroimmunol 174: 101-107.
33. Zhao WL, Daneshpouy ME, Mounier N, Briere J, Leboeuf C, Plassa LF et al. (2004). Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 103:695-697.